The 36-month beta value for COYA is at 0.32. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for COYA is 15.53M, and currently, shorts hold a 1.67% of that float. The average trading volume for COYA on March 04, 2025 was 79.72K shares.
COYA) stock’s latest price update
Coya Therapeutics Inc (NASDAQ: COYA)’s stock price has gone rise by 4.52 in comparison to its previous close of 7.08, however, the company has experienced a 25.42% increase in its stock price over the last five trading days. businesswire.com reported 2025-02-25 that HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast “Is Alzheimer’s next for GLP-1s and Combos?” on February 27, 2025 to discuss the potential treatment of Al.
COYA’s Market Performance
COYA’s stock has risen by 25.42% in the past week, with a monthly rise of 26.28% and a quarterly rise of 15.99%. The volatility ratio for the week is 11.83% while the volatility levels for the last 30 days are 9.02% for Coya Therapeutics Inc The simple moving average for the past 20 days is 12.69% for COYA’s stock, with a 11.84% simple moving average for the past 200 days.
Analysts’ Opinion of COYA
Many brokerage firms have already submitted their reports for COYA stocks, with D. Boral Capital repeating the rating for COYA by listing it as a “Buy.” The predicted price for COYA in the upcoming period, according to D. Boral Capital is $15 based on the research report published on December 04, 2024 of the previous year 2024.
COYA Trading at 22.15% from the 50-Day Moving Average
After a stumble in the market that brought COYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.78% of loss for the given period.
Volatility was left at 9.02%, however, over the last 30 days, the volatility rate increased by 11.83%, as shares surge +21.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.74% upper at present.
During the last 5 trading sessions, COYA rose by +25.42%, which changed the moving average for the period of 200-days by -8.42% in comparison to the 20-day moving average, which settled at $6.57. In addition, Coya Therapeutics Inc saw 29.14% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COYA starting from SNYDER DAVID S, who purchase 1,800 shares at the price of $7.19 back on Nov 14 ’24. After this action, SNYDER DAVID S now owns 8,800 shares of Coya Therapeutics Inc, valued at $12,934 using the latest closing price.
Swaminathan Arun, the Chief Executive Officer of Coya Therapeutics Inc, purchase 5,000 shares at $7.36 during a trade that took place back on Nov 13 ’24, which means that Swaminathan Arun is holding 10,000 shares at $36,797 based on the most recent closing price.
Stock Fundamentals for COYA
Current profitability levels for the company are sitting at:
- -1.17 for the present operating margin
- 1.0 for the gross margin
The net margin for Coya Therapeutics Inc stands at -1.12. The total capital return value is set at -0.34. Equity return is now at value -50.83, with -45.10 for asset returns.
Currently, EBITDA for the company is -7.88 million with net debt to EBITDA at 2.74. When we switch over and look at the enterprise to sales, we see a ratio of 9.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.31.
Conclusion
In conclusion, Coya Therapeutics Inc (COYA) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
